Table 1.
Characteristic | mRNA Array(n = 34) |
Validation Set(n = 146) |
||
---|---|---|---|---|
No. | % | No. | % | |
Age at diagnosis, years | ||||
Mean | 68 | 66 | ||
Range | 44-90 | 31-92 | ||
Male sex | 25 | 74 | 96 | 66 |
Stage at MCC presentation* | ||||
I | 10 | 29 | 47 | 33 |
II | 3 | 9 | 31 | 22 |
III | 18 | 53 | 60 | 42 |
IV | 3 | 9 | 6 | 4 |
Lesion type studied* | ||||
Primary | 9 | 31 | 113 | 80 |
Regional metastasis/rec | 15 | 52 | 25 | 18 |
Distant metastasis | 5 | 17 | 5 | 4 |
MCPyV DNA detectable? | ||||
Yes | 19 | 70 | 40 | 75 |
No | 8 | 30 | 13 | 25 |
NOTE. Patients represented in the validation set were entirely nonoverlapping with patients represented in the mRNA array set. Stage information was not available for seven patients; lesion type information was not available for eight patients; and MCPyV DNA status was not available for 100 patients. Patients with nodal presentation and unknown primary are represented in the regional metastasis category (n = 14).
Abbreviations: MCC, Merkel cell carcinoma; rec, recurrence; MCPyV, Merkel cell polyomavirus.
Significant differences (P < .05) between array and validation set.